Selective acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor (IC50 = 0.073 μM). Lowers non-high density lipoprotein (HDL)-cholesterol and increases HDL-cholesterol concentrations in rats with pre-established dyslipidemia. Orally active. Also inhibits Golgi-associated LPL acyltransferase (LPAT) activity (IC50 = 15 μM).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 393.57. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.54 mL||12.7 mL||25.41 mL|
|5 mM||0.51 mL||2.54 mL||5.08 mL|
|10 mM||0.25 mL||1.27 mL||2.54 mL|
|50 mM||0.05 mL||0.25 mL||0.51 mL|
References are publications that support the biological activity of the product.
Krause et al (1993) In vivo evidence that the lipid-regulating activity of ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J.Lipid Res. 34 279 PMID: 8429262
Sliskovic and White (1991) Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. TiPS. 12 194
Drecktrah et al (2003) Inhibition of a Golgi complex lysophospholipid acyltransferase induces membrane tubule formation and retrograde trafficking. Mol.Biol.Cell 14 3549
If you know of a relevant reference for CI 976, please let us know.
View Related Products by Product Action
Keywords: CI 976, CI 976 supplier, Acyl-CoAcholesterol, acyltransferase, ACAT, inhibitors, inhibits, Transferases, CI976, Acyl-CoA:Cholesterol, Acyltransferase, 2227, Tocris Bioscience
2 Citations for CI 976
Citations are publications that use Tocris products. Selected citations for CI 976 include:
Schmidt and Brown (2009) Lysophosphatidic acid acyltransferase 3 regulates Golgi complex structure and function. J Cell Biol 186 211 PMID: 19635840
Pagliuso et al (2016) Golgi membrane fission requires the CtBP1-S/BARS-induced activation of lysophosphatidic acid acyltransferase δ Nature Communications 7 12148 PMID: 27401954
Do you know of a great paper that uses CI 976 from Tocris? Please let us know.
Reviews for CI 976
There are currently no reviews for this product. Be the first to review CI 976 and earn rewards!
Have you used CI 976?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.